BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Legend Biotech Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Legend Biotech Corporation's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04133636-3161@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of JNJ-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Ther
 apy Directed Against B-cell Maturation Antigen (BCMA) in Participants With
  Multiple Myeloma\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041336
 36
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3161@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of
  Participants With High-Risk Multiple Myeloma\nEstimated primary completio
 n: 26 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ci
 ltacabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149857-3161@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT07149857)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel\nEst
 imated primary completion: 12 April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07149857
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3161@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Bortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by 
 Cilta-cel\, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by L
 enalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diag
 nosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEs
 timated primary completion: 14 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3161@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Different Sequences of Cilta-cel\, Talquetamab in Combination 
 With Daratumumab and Teclistamab in Combination With Daratumumab Following
  Induction With Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone 
 in Participants With Standard-risk Newly Diagnosed Multiple Myeloma\nEstim
 ated primary completion: 2 September 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
